Business Context and Reporting Period
This Form 8-K Current Report from Silexion Therapeutics Corp (SLXN) covers the date of May 29, 2026. The filing reports the effective implementation of a previously approved 1-for-10 reverse share split and the corresponding adjustments to outstanding warrants.
Key Financial Metrics
This filing is a corporate action report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes Versus Prior Period
- Reverse Share Split: A 1-for-10 reverse share split became effective after the close of trading on May 28, 2026. Shares began trading on an adjusted basis on May 29, 2026.
- Share Capital: Authorized share capital remains at $796,500, now consisting of 5,900,000 ordinary shares. The par value increased from $0.0135 to $0.135 per share.
- Warrant Adjustments:
- Shares issuable per warrant decreased to 1/10th of an ordinary share.
- Exercise price increased ten-fold to $15,525.00 per post-split ordinary share.
- Fractional shares will be rounded up to the nearest whole number upon exercise, subject to payment of the full exercise price.
- Identifiers: The trading symbol remains "SLXN" for shares and "SLXNW" for warrants. The new CUSIP for ordinary shares is G1281K148.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors beyond the mechanics of the share split. The primary contingency noted is the rounding of fractional shares upon warrant exercise, which requires payment of the full exercise price for the rounded whole number of shares.
Investor Verification Checklist
- Verify the new CUSIP number for ordinary shares (G1281K148) in brokerage accounts.
- Confirm the adjusted warrant exercise price of $15,525.00 and the reduced share entitlement (1/10th share per warrant).
- Review the rounding policy for fractional shares resulting from warrant exercises.
- Check the trading status of SLXN and SLXNW on the Nasdaq Capital Market effective May 29, 2026.